Christiana Care CCOP was originally funded by NCI in 1987 and has continued since that time. It was organized to facilitate participation in CALGB, NSABP, CCG, RTOG and MD Anderson clinical trials by community physicians in the region. Christiana Care Health Services (CCHS) has a long standing relationship with CALGB, NSABP and COG and has participated in patient accrual since 1966. RTOG and MD Anderson were later added as research bases as was ECOG. We have an extensive catchment area which encompasses all of Delaware, and portions of New Jersey, northeastern Maryland, and southeastern Pennsylvania (Montgomery, Delaware and Chester counties). Delaware ranks fourth in the nation for all cancer sites, third for breast cancer. Maryland ranks third for colorectal cancer, New Jersey second and Pennsylvania fourth. Our CCOP represents a population base in excess of 2.4 million people with extensive protocol entry potential. CCOP investigators, project coordinators and data managers continue to participate in Core Committees of CALGB, NSABP, COG, RTOG, ECOG and MD Anderson research bases. In 1999 when the most current grant award was made, it was noted by the reviewers that cancer prevention and control credits were less than optimal given the treatment credits. In addition the reviewers felt that the number of affiliates had become unwieldy. Over the last three years we have been successful in increasing cancer prevention/control accruals and have addressed the affiliate issue by dropping those that had been unproductive. The overall impact of this grant will be to assure continuation and stimulate expansion of CCOP activities, including treatment and cancer control research, at CCHS and its affiliates throughout our catchment area. One hundred twenty treatment and 130 cancer control credits will be accrued during the next grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045418-20
Application #
7071067
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Sgambati, Maria
Project Start
1987-08-05
Project End
2007-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
20
Fiscal Year
2006
Total Cost
$1,035,003
Indirect Cost
Name
Christiana Care Health Services, Inc.
Department
Type
DUNS #
077069243
City
Newark
State
DE
Country
United States
Zip Code
19713
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Rizzieri, David A; Johnson, Jeffrey L; Byrd, John C et al. (2014) Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 165:102-11
Shulman, Lawrence N; Berry, Donald A; Cirrincione, Constance T et al. (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32:2311-7

Showing the most recent 10 out of 100 publications